Adjuvant drugs in management of osteoarthritis: spotlight on type II collagen


  • Vijay Kakatkar Department of Orthopaedics, Ramkrishna Medical Research Centre, Nashik, Maharashtra, India
  • A. K. Pal Department of Orthopaedics, SSKM Medical College, IPGMER, Kolkata, West Bengal, India
  • Raghuveer Reddy Department of Orthopaedics, Sai Institute of Sports Injury and Arthroscopy, Hyderabad, Telangana, India
  • Ravi Dashputra Department of Orthopaedics, Dashputra Orthopedic Hospital, Nagpur, Maharashtra, India
  • Sanjay Kamble Department of Medical Affairs, Wockhardt Ltd., BKC, Mumbai, Maharashtra, India
  • Hiten Saresa Department of Medical Affairs, Wockhardt Ltd., BKC, Mumbai, Maharashtra, India
  • Rishi Jain Department of Medical Affairs, Wockhardt Ltd., BKC, Mumbai, Maharashtra, India



Type II collagen, Osteoarthritis, Inflammation, Pain, Quality of life, Adjuvant


Osteoarthritis (OA) is a common musculoskeletal disorder that affects large and small joints and is seen in all ages due to diverse aetiologies. Pain, joint stiffness and limitation of daily activities affects the quality of life of individuals with OA. Conventional analgesics like non-steroidal anti-inflammatory drugs affect pain and inflammatory component but do not target the disease pathogenesis. Damage to the joint cartilage is central to the pathogenesis of OA. Better understanding of the pathogenesis has led to evolution of various adjuvant drugs in management of OA. Among them, undenatured type II collagen induces immune tolerance and thereby provide benefits by reducing the joint damage. Studies assessing efficacy and safety of undenatured type II collagen in OA have shown to reduce clinical symptoms like pain, joint stiffness and improvement in physical activities, and thus improving the quality of life. It is well tolerated and safe for use in OA. This article discusses the pathophysiology of OA with inflammation and beyond, and overviews the various drugs that are used as adjuvants in the management of OA with special focus on the use of type 2 collagen.


Flores RH, Hochberg MC. In Osteoarthritis. In: Brandt KD, Doherty M, Lohmander LS, eds. Oxford Univ. Press, 2003; pp: 1–8.

Sellam J, Berenbaum F. Is osteoarthritis a metabolic disease? Joint Bone Spine. 2013;80:568–73.

Pelletier MJ, Wildi LM, Pelletier JP. Future therapeutics for osteoarthritis. Bone. 2012;51:297–311.

Spector TD, Cooper C. Radiographic assessment of osteoarthritis in population studies:whither Kellgren and Lawrence? Osteoarthritis Cartilage. 1993;1:203–6.

Chen D, Shen J, Zhao W, Wang T, Han L, Hamilton JL, et al. Osteoarthritis: toward a comprehensive understanding of pathological mechanism. Bone Res. 2017;5:16044.

Laupattarakasem W, Laopaiboon M, Laupattarakasem P, Sumananont C. Arthroscopic debridement for knee osteoarthritis. Cochrane Database of Syst Rev. 2008;1:CD005118.

Crowley DC, Lau FC, Sharma P, Evans M, Guthrie N, Bagchi M. Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial. Int J Med Sci. 2009;6:312- 21.

Lugo JP, Saiyed ZM, Lane NE. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: A multicenter randomized, double-blind, placebo-controlled study. Nutr J. 2016;15:14.

Guccione AA, Felson DT, Anderson JJ, Anthony JM, Zhang Y, Wilson PW, et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health. 1994;84:351–8.

Zhu P, Li XY, Wang HK, Jia JF, Zheng ZH, Ding J, et al. Oral administration of type-II collagen peptide 250–270 suppresses specific cellular and humoral immune response in collagen-induced arthritis. Clin Immunol. 2007;122:75–84.

Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-128.

Priority disease and reasons for inclusion. Osteoarthritis. Available at: medicines/areas/priority_medicines/Ch6_12Osteo.pdf. Accessed on 3 January 2019.

Pal CP, Singh P, Chaturvedi S, Pruthi KK, Vij A. Epidemiology of knee osteoarthritis in India and related factors. Indian J Orthop. 2016;50(5):518-22.

Suri S, Walsh DA. Osteochondral alterations in osteoarthritis. Bone. 2012;51:204–11.

Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone. 2012;51:249–57.

Wang X, Hunter D, Xu J, Ding C. Metabolic triggered inflammation in osteoarthritis. Osteoarthritis Cartilage. 2015;23:22–30.

Malfait AM. Osteoarthritis year in review 2015:biology. Osteoarthritis Cartilage. 2016;24:21-6.

Yang X, Chen L, Xu X, Li C, Huang C, Deng CX. TGF-β/Smad3 signals repress chondrocyte hypertrophic differentiation and are required for maintaining articular cartilage. J Cell Biol. 2001;153:35–46.

Musumeci G. The effect of mechanical loading on articular cartilage. J Funct Morphol Kinesiol. 2016;1:154–61.

Zhu M, Tang D, Wu Q, Hao S, Chen M, Xie C, et al. Activation of β-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult β-catenin conditional activation mice. J Bone Miner Res. 2009;24:12–21.

Thirunavukkarasu K, Pei Y, Wei T. Characterization of the human ADAMTS-5 (aggrecanase-2) gene promoter. Mol Biol Rep. 2007;34:225–31.

ANON. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arth Rheum. 2000;43:1905-15.

Fernandes L, Hagen KB, Bijlsma JW, Andreassen O, Christensen P, Conaghan PG, et al. EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann. Rheum. Dis. 2013;72:1125–35.

Fransen M, McConnell S, Hernandez Molina G, Reichenbach S. Exercise for osteoarthritis of the hip. Cochrane Database Syst Rev. 2014;4:CD007912.

Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010;18:476–99.

Roberts E, Nunes VD, Buckner S, Latchem S, Constanti M, Miller P, et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis. 2016;75:552–9.

Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015;1:CD005614.

Bruyère O, Cooper C, Pelletier JP, Branco J, Brandi ML, Guillemin F, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally:a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014;44:253–63.

di Padova C. S-adenosylmethionine in the treatment of osteoarthritis. Review of the clinical studies. Am J Med. 1987;83:60-5.

Najm WI, Reinsch S, Hoehler F, Tobis JS, Harvey PW. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms:a double-blind cross-over trial.[ISRCTN36233495]. BMC Musculoskeletal Disorders. 2004;5:6.

Clegg DO, Reda DJ, Harris CL, Klein MA, O’Dell JR, Hooper MM, et al. Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis. N Engl J Med. 2006;354:795-808.

Zhu X, Sang X, Wu D, Ring J, Jiang L. Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis:a meta-analysis of randomized controlled trials. J Orthop Surg Res. 2018;13:170.

Yimam M, Horm T, Wright L, Jiao P, Hong M, Brownell L, et al. Cartilage Protection and Analgesic Activity of a Botanical Composition Comprised of Morus alba, Scutellaria baicalensis, and Acacia catechu. Evidence-Based Complementary Alternative Med. 2017:7059068.

Arjmandi BH, Omsbee LT, Elam ML, Campbell SC, Rahnama N, Payton ME, et al. A Combination of Scutellaria Baicalensis and Acacia Catechu Extracts for Short-Term Symptomatic Relief of Joint Discomfort Associated with Osteoarthritis of the Knee. J Med Food. 2014;17:707–13.

Hashempur MH, Sardneshin S, Mosavat SH, Ashraf A. Green tea (Camellia sinensis) for patients with knee osteoarthritis:A randomized open-label active-controlled clinical trial. Clin Nutr. 2018;37:85-90.

Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A. Curcuminoid Treatment for Knee Osteoarthritis: A Randomized Double-Blind Placebo-Controlled Trial. Phytother Res. 2014;28:1625–31.

Ying X, Chen X, Cheng S, Shen Y, Peng L, Xu HZ. Piperine inhibits IL-β induced expression of inflammatory mediators in human osteoarthritis chondrocyte. Int Immunopharmacol. 2013;17:293–9.

Siddiqui MZ. Boswellia serrata, a potential anti-inflammatory agent:an overview. Indian J Pharm Sci. 2011;73(3):255-61.

Suva MA, Kheni DB, Sureja VP. Management strategies for knee osteoarthritis:Aflapin® (Boswellia serrata extract). Ayu. 2017;38(1-2):94.

Ramakanth GS, Uday Kumar C, Kishan PV, Usharani P. A randomized, double blind placebo-controlled study of efficacy and tolerability of Withaina somnifera extracts in knee joint pain. J Ayurveda Integr Med. 2016;7(3):151-7.

Bartels EM, Folmer VN, Bliddal H, Altman RD, Juhl C, Tarp S, Zhang W, Christensen R. Efficacy and safety of ginger in osteoarthritis patients:a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage. 2015 Jan;23(1):13-21.

Boe C, Vangsness CT. Fish Oil and Osteoarthritis: Current Evidence. Am J Orthop (Belle Mead NJ). 2015;44:302-5.

Hill CL, March LM, Aitken D, Lester SE, Battersby R, Hynes K, et al. Fish oil in knee osteoarthritis:a randomised clinical trial of low dose versus high dose Ann Rheum Dis. 2016;75:23–9.

Bohlooli S, Jastan M, Nakhostin-Roohi B, Mohammadi S, Baghaei Z. A pilot double-blinded, randomized, clinical trial of topical virgin olive oil versus piroxicam gel in osteoarthritis of the knee. J Clin Rheumatol. 2012;18:99–101.

Christiansen BA, Bhatti S, Goudarzi R, Emami S. Management of Osteoarthritis with Avocado/Soybean Unsaponifiables. Cartilage. 2015;6:30-44.

Maheu E, Cadet C, Marty M, Moyse D, Kerloch I, Coste P, et al. Randomised, controlled trial of avocado–soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Ann Rheum Dis. 2014;73(2):376-84.

Poole AR. Cartilage in health and disease. In: Koopman W, ed. Arthritis and allied conditions. A textbook of rheumatology. 14th Ed. Philadelphia: Lippincott, Williams and Wilkins; 2001: 226–284.

Poole AR, Rosenberg LC, Reiner A, Ionescu M, Bogoch E, Roughley PJ. Contents and distributions of the proteoglycans decorin and biglycan in normal and osteoarthritic human articular cartilage. J Orthop Res. 1996;14:681–9.

Hollander AP, Heathfield TF, Webber C, Iwata Y, Rorabeck C, Bourne R, et al. Increased damage to type II collagen in osteoarthritic cartilage detected by a new immunoassay. J Clin Inves. 1994;93:1722–32.

van Vijven JP, Luijsterburg PA, Verhagen AP, van Osch GJ, Kloppenburg M, Bierma-Zeinstra SM. Symptomatic and chondroprotective treatment with collagen derivatives in osteoarthritis:a systematic review. Osteoarthritis Cartilage. 2012;20:809-21.

Kyung-Su P, Min-Jung P, Mi-La C, Seung-Ki K, JiHyeon J, Hyeok-Jae K, et al. Type II collagen oral tolerance;mechanism and role in collagen-induced arthritis and rheumatoid arthritis. Mod Rheumatol. 2009;19:581-9.

Tong T, Zhao W, Wu YQ, Chang Y, Wang QT, Zhang LL, et al. Chicken type II collagen induced immune balance of main subtype of helper T cells in mesenteric lymph node lymphocytes in rats with collagen-induced arthritis. Inflamm Res. 2010;59:369–77.

Weiner HL, da Cunha AP, Quintana F, Wu H. Oral tolerance. Immunol Rev. 2011;241:241–59.

Li MO, Flavell RA. TGF-beta: a master of all T cell trades. Cell. 2008;134:392–404.

Coombes JL, Siddiqui KR, Arancibia-Cárcamo CV, Hall J, Sun CM, Belkaid Y, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med. 2007;204:1757–64.

Ilan Y, Zigmond E, Lalazar G, Dembinsky A, Ya’acov AB, Hemed N, et al. Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells. J Clin Immunol. 2010;30:167–77.

Bagi CM, Berryman ER, Teo S, Lane NE. Oral administration of undenatured native chicken type II collagen (UC-II) diminished deterioration of articular cartilage in a rat model of osteoarthritis (OA). Osteoarthritis Cartilage. 2017;25:2080- 90.

Di Cesare Mannelli L, Micheli L, Zanardelli M, Ghelardini C. Low dose native type II collagen prevents pain in a rat osteoarthritis model. BMC Musculoskeletal Disorders. 2013;14:228.

Lugo JP, Saiyed ZM, Lau FC, Molina JPL, Pakdaman MN, Shamie AN. Undenatured type II collagen (UC-II®) for joint support:a randomized, double-blind, placebo-controlled study in healthy volunteers. J Int Society Sports Nutr. 2013;10:48.

Lerman et al. Nutritional Approach for Relief of Joint Discomfort in a form of A 12-week, Open-case Series and Illustrative Case Report. Integr Med (Encinitas). 2015;14:52–61.

Mehra A, Anand P, Borate M, Paul P, Kamble S, Mehta KD, et al. A non-interventional, prospective, multicentric real life Indian study to assess safety and effectiveness of un-denatured type 2 collagen in management of osteoarthritis. Int J Res Orthop. 2019;5:315-20.

Gupta RC, Canerdy TD, Lindley J, Konemann M, Minniear J, Carroll BA, et al. Comparative therapeutic efficacy and safety of type-II collagen (UC-II®), glucosamine and chondroitin in arthritic dogs:Pain evaluation by ground force plate. J Anim Physiol Anim Nutr. 2012;96:770–7.

Park KS, Park MJ, Cho ML, Kwok SK, Ju JH, Ko HJ, et al. Type II collagen oral tolerance:Mechanism and role in collagen-induced arthritis and rheumatoid arthritis. Mod. Rheumatol. 2009;19:581–9.

Lopez HL. Nutritional interventions to prevent and treat osteoarthritis—Part II:Focus on micronutrients and supportive nutraceuticals. PM R. 2012;4:S155–S168.






Review Articles